1. The next generation platform for the isolation of fully human monoclonal antibodies
Corporate Overview Co

2. Our Mission
Trianni is a biotech company with the primary scientific mission of creating an optimized and highly versatile platform for isolating fully human monoclonal antibodies.

3. Management Team
Dr. Matthias Wabl, Ph.D., Chairman & Chief Executive Officer
Dr. Wabl was a cofounder and managing partner of Picobella, LLC, and a co-founder of Sagres Discovery, Inc. (now Novartis), where he served as President and as Chair, Scientific Advisory Board. He has been a member of the NIH, Small Business Innovative Research Study Section and an advisor to numerous biotechnology companies and the FDA. He is also a Professor of Microbiology and Immunology at the University of California at San Francisco (UCSF) where he has been engaged in research on the generation of antibody diversity and the basis of autoimmunity for over 20 years. He received his Ph.D. from the Max-Planck Institute in Berlin. 
Dr. Zishan Haroon, M.D., Ph.D., Chief Business Officer
Z Haroon MD PhD is the business and corporate development lead for Trianni. He comes with extensive experience in drug discovery and development over last two decades. In addition, he has managed business and corporate functions in both Venture and Private Equity for last 15 years.
Dr. Nigel Killeen, D.Phil., Chief Scientific Officer
Before moving full-time to Trianni, Dr. Killeen was Associate Professor of Microbiology and Immunology at the University of California at San Francisco (UCSF). In addition to directing a highly active research program in T lymphocyte biology, Dr. Killeen was also the director of the UCSF Transgenic and Targeted Mutagenesis facility responsible for generating genetically engineered mice for researchers in and outside the UCSF community. Dr. Killeen received his Ph.D. from Oxford University in England; he has served as a consultant to numerous biotechnology companies and has been a permanent member of the NIH Cellular and Molecular Immunology Scientific Review Panel.. 
Dr. Maria Wabl, M.D., Chief Financial Officer
Dr. Wabl has held positions at the Max-Planck Institute in Tübingen and at the Robert-Bosch Hospital, Stuttgart, Germany. She served as fundraiser, member of the board and president of several schools in the San Francisco Bay Area. Dr. Wabl received her M.D. from the University of Tübingen, Germany.

4. Core Values provide the best in class antibody platform
operate efficiently
be responsive to our clients needs

5. The Trianni MouseTM Difference

6. The Trianni MouseTM Technology Approach
Generation of Immunoglobulin H, K and λ “Acceptor Alleles” (ES cells)
Design of alleles
Complete repertoire of variability gene segments
Deletion of V, D, and J gene segments
Retention of endogenous IgH class switching DNA
Mouse regulatory sequences (promoters)
Ready for “recombinase-mediated cassette exchange” (RMCE)
Human coding sequences
Optimizations throughout
Gene synthesis
Modification of ES cells by RMCE and generation of mice

7. The Trianni MouseTM Platform

8. A Highly Diverse Heavy Chain Repertoire
44/44 VHs used

9. H CDR3 Length Distribution
IgM-Sorted Naïve B cells

10. Heavy Chain CDR3 Compositions
CDR3s of 15aa in length
Human
Trianni

11. Trianni Mice: Replete With B Cells and Antibodies

12. External Anti-Target 2 Abs are potent inhibitors of cytokine production

13. The Trianni MouseTM – Advantages

14. How does our partnership work?

15. Strategic CRO Partnerships

16. Business Development
2010
2011
2012
2013
2014
2015
2016
2017
Allele design
and gene targeting
Single
Double
Triple
Platform assembly (breeding) and validation
Licensing; platform refinements and enhancements
Further enhanced alleles (more diversity, improved rearrangement efficiency…)
Add-ons ,e.g., that allow for access to antigen-specific plasma cell repertoires
Alleles that diversify non-antibody “scaffold” domains
A novel bispecific antibody platform

17. TRIANNI Benefits
Small company means: - easy access to our experts - lean processes (quicker time to use of our platform) - personal relationships
60 years combined industry experience
Representation in key biotech locations - San Francisco, CA (West Coast, USA) - Research Triangle Park, NC (East Coast, USA) - Germany (Europe)
Flexibility to create a custom partnership to match your needs
Forward-thinking leadership
Faster turn-around time
Technical support, if needed
An investment in your company. We value our partners and want you to succeed!

18. Contact Us 1.866.374.9314 info@trianni.com www.trianni.com